| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1894 | 2018 |
| Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer J Tie, JD Cohen, K Lahouel, SN Lo, Y Wang, S Kosmider, R Wong, ... New England Journal of Medicine 386 (24), 2261-2272, 2022 | 566 | 2022 |
| Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a … AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, ... JAMA oncology 6 (4), 519-527, 2020 | 368 | 2020 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The Lancet Oncology 22 (5), 643-654, 2021 | 337 | 2021 |
| Impact of the COVID-19 pandemic on cancer care: a global collaborative study AR Jazieh, H Akbulut, G Curigliano, A Rogado, AA Alsharm, ED Razis, ... JCO global oncology 6, 1428-1438, 2020 | 265 | 2020 |
| Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial AMM Eggermont, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, ... Journal of clinical oncology 38 (33), 3925-3936, 2020 | 261 | 2020 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 240 | 2018 |
| Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study JS Weber, MS Carlino, A Khattak, T Meniawy, G Ansstas, MH Taylor, ... The Lancet 403 (10427), 632-644, 2024 | 128 | 2024 |
| Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma CN Owen, X Bai, T Quah, SN Lo, C Allayous, S Callaghan, ... Annals of Oncology 32 (7), 917-925, 2021 | 109 | 2021 |
| Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, ... European Journal of Cancer 116, 148-157, 2019 | 88 | 2019 |
| Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma V Atkinson, A Khattak, A Haydon, M Eastgate, A Roy, P Prithviraj, ... Journal for immunotherapy of cancer 8 (2), 2020 | 87 | 2020 |
| Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, ... NEJM evidence 1 (11), EVIDoa2200214, 2022 | 79 | 2022 |
| Effects of salicylic acid on growth and accumulation of phenolics in Zea mays L. under drought stress F Latif, F Ullah, S Mehmood, A Khattak, AU Khan, S Khan, I Husain Acta Agriculturae Scandinavica, Section B—Soil & Plant Science 66 (4), 325-332, 2016 | 79 | 2016 |
| Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study DH Lee, MS Tsao, KO Kambartel, H Isobe, MS Huang, CH Barrios, ... PLoS One 13 (8), e0202865, 2018 | 69 | 2018 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised … A Bottomley, C Coens, J Mierzynska, CU Blank, M Mandalà, GV Long, ... The lancet oncology 22 (5), 655-664, 2021 | 58 | 2021 |
| Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. A Khattak, JS Weber, T Meniawy, MH Taylor, G Ansstas, KB Kim, ... Journal of Clinical Oncology 41 (17_suppl), LBA9503-LBA9503, 2023 | 51 | 2023 |
| Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis P Bhave, L Pallan, GV Long, AM Menzies, V Atkinson, JV Cohen, ... British Journal of Cancer 124 (3), 574-580, 2021 | 47 | 2021 |
| Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety … A Khattak, M Carlino, T Meniawy, G Ansstas, T Medina, MH Taylor, ... Cancer Research 83 (8_Supplement), CT001-CT001, 2023 | 36 | 2023 |
| Effect of waste water treated with TiO2 nanoparticles on early seedling growth of Zea mays L. S Yaqoob, F Ullah, S Mehmood, T Mahmood, M Ullah, A Khattak, MA Zeb Journal of Water Reuse and Desalination 8 (3), 424-431, 2018 | 36 | 2018 |
| Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma OJ Kennedy, M Kicinski, S Valpione, S Gandini, S Suciu, CU Blank, ... European journal of cancer 165, 97-112, 2022 | 31 | 2022 |
